ADC Therapeutics is seeking accelerated approval from the FDA for its Zynlonta therapy.
2 reports, 2 independent
Updated Aug 27
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
ADC Therapeutics is seeking accelerated approval from the FDA for its Zynlonta therapy.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA flagged serious safety concerns about ZYNLONTA combination.1 source
ADC Therapeutics is seeking accelerated FDA approval for its Zynlonta therapy.1 source
Keep exploring
The entities involved
-
ADC Therapeutics
company in Épalinges, Switzerland
Nothing else this week.
- FDA